Zura Bio Limited Class A Ordinary Shares (ZURA)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with what is knowable. Zura Bio is a clinical-stage biotech with 40 employees, no reported revenue, and two antibody candidates: Tibulizumab in Phase 2 and Torudokimab (ZB-880). The science may be promising, but there is no demonstrated commercial moat yet; biotech moats appear only after trial validation, patents, and regulatory approval. The filed figures show persistent losses. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $26.3M and diluted EPS was -$0.21. In fiscal Q2 2025, the quarter ended 2025-06-30, net loss was $16.0M, so the loss is widening. For fiscal 2025, the year ended 2025-12-31, net loss was $68.7M; fiscal 2024, the year ended 2024-12-31, net loss was $52.4M; and fiscal 2023, the year ended 2023-12-31, net loss was $60.4M. Trailing free cash flow is -$77.6M, and FairStock's FCF yield is -19.2%. ROE is -51.01% and ROCE is -31.23%. The FairStock Piotroski F-Score is 0/9, and the FairStock Score is 16/100. Valuation is difficult: at the $4.23 close on 2026-10-13, the P/E is -3.78 and P/B is 2.05. Paying about twice book for a loss-making, cash-burning story is not Graham's margin of safety. The Lynch category is none because the company lost money in each of the last four years. Growth is not revenue growth; it is pipeline progress. Until data or a partner validates it, this is speculation, not a proven investment.

In plain English: Zura Bio is a small drug development company with no reported sales yet, working on experimental antibody treatments for autoimmune and inflammatory conditions. It has lost money every year for at least four years and burned $77.6 million in cash over the last year, so the business currently looks weak. At $4.23 a share, there are no profits or sales to judge whether the price is cheap or expensive; it looks like a high-risk bet on future drug trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer